logo

Avrobio, Inc. (AVRO)



Trade AVRO now with
  Date
  Headline
8/9/2019 8:11:01 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) FY20 Estimate To -2.46 From -3.23
8/9/2019 8:10:19 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q4 20 Estimate To -0.65 From -0.84
8/9/2019 8:10:09 AM Wedbush Is Raising AVROBIO, INC. (AVRO) Q3 20 Estimate To -0.65 From -0.85
8/9/2019 8:09:56 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q2 20 Estimate To -0.59 From -0.78
8/9/2019 8:09:44 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q1 20 Estimate To -0.57 From -0.76
8/9/2019 8:09:32 AM Wedbush Is Raising AVROBIO, INC. (AVRO) FY19 Estimate To -2.46 From -2.88
8/9/2019 8:09:21 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q4 19 Estimate To -0.54 From -0.71
8/9/2019 8:09:11 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q3 19 Estimate To -0.54 From -0.69
8/9/2019 8:08:47 AM Wedbush Reiterates AVROBIO, INC. (AVRO) At Outperform With $43 Price Target
7/16/2019 10:14:56 PM AVROBIO Prices Underwritten Public Offering Of 6.50 Mln Shares At $18.50/shr
7/15/2019 7:09:54 AM AVROBIO Reports 87% Substrate Reduction In First Kidney Biopsy And Addl Positive Data From Clinical Trials Of AVR-RD-01
2/7/2019 8:25:19 AM Wedbush Reiterates AVROBIO, INC. (AVRO) At Outperform With $43 Price Target
2/6/2019 9:05:48 AM AVROBIO Announces Updated Clinical Data From Phase 1 And Phase 2 Studies For AVR-RD-01 Gene Therapy For Fabry Disease
1/18/2019 7:06:32 AM AVROBIO Announces Acceptance Of IND Application For Phase 1/2 Clinical Trial For AVR-RD-04 Gene Therapy For Cystinosis
1/7/2019 7:07:22 AM AVROBIO Appoints Philip Vickers To Its Board